{"id":141492,"title":"Avacta Therapeutics Raises £12.5m as Trading Resumes After Capital Access Window","publisher":"Share Talk","author":"sharetalk","published":"2026-10-06T06:45:12+00:00","modified":"2026-10-06T06:45:12+00:00","canonical_url":"https://www.share-talk.com/avacta-therapeutics-raises-12-5m-as-trading-resumes-after-capital-access-window/","markdown_url":"https://www.share-talk.com/avacta-therapeutics-raises-12-5m-as-trading-resumes-after-capital-access-window.md","json_url":"https://www.share-talk.com/avacta-therapeutics-raises-12-5m-as-trading-resumes-after-capital-access-window.json","category":"Health","categories":["Health","Healthcare","Pharmaceutical"],"tags":["Abingdon Health","AffyXell Therapeutics","antigen","Avacta Group","AVCT","Biotherapeutics","Chris Yates","Christina Coughlin","clinical","COVID-19","Cytiva","Daewoong Pharmaceutical","diagnostic","Doncaster","Europe","LG Chem Life Sciences","Michelle Morrow","Pharma","radiopharmaceuticals","saliva test","SARS-COV-2","Sengho Jeon","Share Talk","South Korea","therapeutic","UK","validation","York"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2026/10/5d4c9eef-cd31-4c97-9f75-62af79111385.png?fit=1727%2C911&ssl=1","format":"news","language":"en-GB","content":"[Avacta Therapeutics (AIM: AVCT)](https://www.investegate.co.uk/announcement/rns/avacta-group--avct/results-of-placing-and-subscription-/9807660)has conditionally raised **£12.5 million gross** through a placing and director subscription priced at 68p per share.\n\nThe company placed **17,411,766 new shares** and issued a further **970,587 subscription shares**, taking the total number of new shares to approximately **18.38 million**.\n\nThe new shares represent around **3.9% of Avacta’s existing issued share capital**.\n\nThe 68p issue price represents a **5.6% discount to the 72p closing mid-market price on 29 September 2026**, the final trading day before Avacta entered its Capital Access Window.\n\nThe fundraising remains conditional on admission of the new shares and the placing agreement not being terminated before admission.\n\nManagement said the proceeds extend Avacta’s cash runway into **Q2 2027** and provide funding through several expected clinical and development milestones.\n\nThe most important is the anticipated **first clinical efficacy data from AVA6103 in H1 2027**.\n\nAVA6103 has already demonstrated clinical proof of mechanism in the Phase 1 FOCUS-01 trial, with Avacta reporting that its controlled-release mechanism is working in patients as intended.\n\nHowever, the forthcoming H1 2027 data remain the first major test of **clinical efficacy**, rather than mechanism or early safety alone.\n\nAvacta is also progressing **AVA6000 through Phase 1b development** and expects to select a clinical candidate for its dual-payload **AVA6207 programme during Q4 2026**, ahead of IND-enabling studies.\n\nChief executive **Christina Coughlin** said the financing strengthened Avacta’s position in ongoing partnering discussions and provided funding through multiple potential value inflection points.\n\nFour directors participated in the subscription, investing approximately **£660,000 in aggregate**.\n\nNon-executive chairman **Richard Hughes contributed £500,000**, while Patrick Vink invested £75,000, David Bryant £50,000 and Mats Blom £35,000.\n\nZeus Capital also subscribed for **180,001 shares at 68p**, representing an investment of approximately £122,401.\n\nBecause Richard Hughes is a director and majority shareholder of Zeus Capital, that participation constitutes a **related-party transaction under AIM Rule 13**.\n\nThe independent directors, after consulting nominated adviser Strand Hanson, concluded that the Zeus participation was fair and reasonable for shareholders.\n\nFollowing completion of the fundraising, Avacta has now **closed its Capital Access Window**, with existing shares expected to resume trading on AIM at **7.30am on 6 October 2026**.\n\nFor investors, the immediate funding risk has been reduced, with Avacta securing the targeted £12.5 million at relatively modest dilution.\n\nThe next valuation drivers are now clinical rather than financing-led: **AVA6207 candidate selection during Q4 2026, continued AVA6000 development and first AVA6103 efficacy data in H1 2027**."}